Ikarian Capital LLC Makes New Investment in Nyxoah S.A. (NASDAQ:NYXH)

Ikarian Capital LLC purchased a new stake in Nyxoah S.A. (NASDAQ:NYXH) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 50,699 shares of the company’s stock, valued at approximately $684,000.

Separately, Iron Triangle Partners LP acquired a new stake in shares of Nyxoah in the first quarter valued at approximately $3,413,000.

Nyxoah Price Performance

NASDAQ NYXH remained flat at $8.36 during mid-day trading on Thursday. 3,773 shares of the company were exchanged, compared to its average volume of 45,637. Nyxoah S.A. has a 1 year low of $4.00 and a 1 year high of $20.00. The firm’s fifty day simple moving average is $8.42 and its two-hundred day simple moving average is $10.46. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.70 and a current ratio of 3.94.

Nyxoah (NASDAQ:NYXH) last announced its earnings results on Tuesday, May 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.45). Nyxoah had a negative net margin of 843.49% and a negative return on equity of 42.14%. The firm had revenue of $1.33 million for the quarter, compared to analyst estimates of $1.20 million. As a group, sell-side analysts anticipate that Nyxoah S.A. will post -1.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on NYXH shares. Cantor Fitzgerald lowered their price target on shares of Nyxoah from $18.00 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 15th. Oppenheimer lowered their price target on shares of Nyxoah from $20.00 to $15.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 15th. Stifel Nicolaus lowered their price target on shares of Nyxoah from $27.00 to $19.00 and set a “buy” rating on the stock in a research report on Monday, June 24th. Finally, HC Wainwright lowered their price target on shares of Nyxoah from $22.00 to $18.00 and set a “buy” rating on the stock in a research report on Friday, May 24th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $17.80.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.